Insights

Rethinking Patient Centricity in a Dynamic Market Access Driven Ecosystem

Understanding the Complexities and Interdependencies that Deliver Successful Outcomes. As the industry moves to a patient-centric, value-based care model, stakeholders across the continuum of care are focused on creating systems and solutions that put the patient…

Ask the Expert – Digital Therapeutics

Are We Transforming In The Right Way?

Articles

“Ask the Expert” About Digital Therapeutics

The promise of digital health – from wearables to mobile health apps – could revolutionize healthcare by improving adherence, reducing costs, and making treatments more personalized. Mike Ryan shares insight on the opportunity to set a…

Rethinking Patient Centricity in a Dynamic Market Access Driven Ecosystem

Understanding the Complexities and Interdependencies that Deliver Successful Outcomes. As the industry moves to a patient-centric, value-based care model, stakeholders across the continuum of care are focused on creating systems and solutions that put the patient…

Strategies to Ensure Market Success of a Rare Disease Product Launch

Small patient populations, complex administration, high costs of therapies, and government policy interventions are just a few obstacles in rare disease. EVERSANA’s Managing Director, Bill O’Bryon, and Senior Director, Diann Johnson, outline key insights to consider…

How to Demonstrate Value to Providers, Payers & Patients

Fact: Primary stakeholders – providers, patients and payers – have greater expectations than ever before. To ensure success at every stage of the product life cycle, it’s imperative to deploy a sophisticated, clinically oriented and data-driven…

More Data, More Problems, More Potential

As the healthcare industry shifts from volume-based care to a value-based reimbursement structure, data analytics will be critical in shaping the future of the pharmaceutical industry. More so than perhaps any recent industry trend, value base…

Ask the Expert – Digital Therapeutics

From reimbursement strategies, distribution, dispensing, patient engagement and adherence programs, EVERSANA offers integrated solutions to alleviate the barriers facing the adoption of digital therapeutics. Mike Ryan, Executive Vice President of Europe and Asia Pacific, discusses how…

What’s next for ICER? Pharmaceutical pricing watchdog to venture beyond the pill.

Earlier in the month, the Institute for Clinical and Economic Review (ICER) issued a call for public input to help identify and prioritize non-drug topics for ICER assessments in 2020. It may seem like the ICER…

Ask the Expert – Specialty Pharmacies and Specialty Distributors

According to a recent study from Health Strategies Insights by EVERSANA, 35%-45% of pipeline drugs are infusions and injectables that require nursing services, patient education, cold chain, new reimbursement measures and sites of care. Where is…

Developing an Optimal Hub to Ensure Product Access

Prior to launching a new Hub, our client, a global biopharmaceutical company, needed to ensure that the services offered would be superior to those of other companies and ensure their product’s access in an increasingly competitive…

The Four Biggest Recruitment Issues for Clinical Operations Teams … And How to Solve Them.

Eighty percent of clinical trials in the United States fail to meet their patient recruitment timelines [1, 2] and 15-20% of activated clinical trial sites never enroll a single patient. [2] Meanwhile, 50% of clinical trial…